Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
VERTEX PHARMACEUTICALS INC / MA (VRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/26/2018 BW Vertex Reports First-Quarter 2018 Financial Results
04/17/2018 BW Vertex to Announce First Quarter 2018 Financial Results on April 26
01/03/2018 BW Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results
10/25/2017 BW Vertex Reports Third-Quarter 2017 Financial Results
10/16/2017 BW Vertex to Announce Third Quarter 2017 Financial Results on October 25
07/26/2017 BW Vertex Reports Second-Quarter 2017 Financial Results
07/13/2017 BW Vertex to Announce Second Quarter 2017 Financial Results on July 26
06/09/2017 BW Vertex to Present at the Goldman Sachs Healthcare Conference on June 13
04/27/2017 BW Vertex Reports First-Quarter 2017 Financial Results
04/12/2017 BW Vertex to Announce First Quarter 2017 Financial Results on April 27
03/28/2017 BW Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis
07/05/2011 BW Vertex Announces the Date of its Second Quarter 2011 Financial Results Conference Call and Webcast
05/26/2011 BW Vertex Announces Webcasts of its Presentations at Two Investor Conferences
05/23/2011 BW FDA Approves INCIVEK™ (telaprevir) for People with Hepatitis C
05/17/2011 BW Vertex Appoints Terrence C. Kearney to its Board of Directors
05/03/2011 BW Vertex Reports First Quarter 2011 Financial Results and Reviews Milestones for Key Development Programs
05/02/2011 BW Vertex Announces Webcasts of its Presentations at Two Investor Conferences
04/28/2011 BW FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C
04/15/2011 BW Vertex Announces the Date of its First Quarter 2011 Financial Results Conference Call and Webcast
04/07/2011 BW Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis
03/31/2011 BW Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status
03/31/2011 BW Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful
03/31/2011 BW Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C
03/29/2011 BW Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks
03/14/2011 BW Vertex Announces Webcast of its Presentation at the Barclays Capital 2011 Global Healthcare Conference
03/10/2011 BW Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment
03/07/2011 BW New Data on Telaprevir and VX-222 for the Treatment of Hepatitis C Accepted For Presentation at EASL Annual Meeting
03/03/2011 BW Vertex Announces Webcast of its Presentation at the Cowen 31st Annual Health Care Conference
03/02/2011 BW Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference
02/25/2011 BW Vertex Announces Webcasts of its Presentations at Two Investor Conferences
02/23/2011 BW Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis
02/11/2011 BW Vertex Announces Webcasts of its Presentations at Two Investor Conferences
11/24/2010 BW Vertex Pharmaceuticals Announces Webcast of its Presentation at the Piper Jaffray 22nd Annual Health Care Conference
11/23/2010 BW Vertex Completes New Drug Application for Telaprevir for Hepatitis C
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy